Clinical Trial Update: GlyT-1 Inhibitor Treatment for Refractory Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update reporting completion of testing for a GlyT-1 inhibitor in treatment-refractory schizophrenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia
• Treatment-resistant Schizophrenia

Drugs mentioned

• GlyT-1 inhibitor

Snippet

Sponsor: China Medical University Hospital | Conditions: Schizophrenia, Treatment Refractory | Phase 2 | Status: COMPLETED